LLY
Eli Lilly and Company
LLY has the edge over PBYI overall, supported by stronger valuation and stronger fundamentals.
PBYI
Puma Biotechnology, Inc.
PBYI trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PBYI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Strong |
PBYI's cash flow and balance sheet are currently strong, and its revenue and profitability are stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over PBYI in the historical PE scenario, which offers more potential upside but is not a forecast.
PBYI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.4x | $2.49 | -69% |
| Fair | 12x | $5.71 | -29% |
| Current | 18x | $8.08 | — |
| Expensive | 22x | $10.08 | +25% |
Historical ranges are pointers, not guarantees.
PBYI's PE is in its expensive range at 18x.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PBYI Forward outlook
There aren't enough analyst estimates for PBYI to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PBYI on earnings, with more consistent year-over-year improvement.
PBYI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.46 | -39% |
| Q2 2026 | $0.52 | -47% |
| Q1 2026 | $0.48 | -38% |
| Q4 2025 | $0.61 | -1.6% |
| Q3 2025 | $0.75 | +60% |
| Q2 2025 | $0.99 | +450% |
| Q1 2025 | $0.78 | +144% |
| Q4 2024 | $0.62 | +38% |
PBYI's earnings per share have fallen from their peak: $0.46 over the past year, against $0.99 in mid-2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PBYI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PBYI on profitability, with a higher operating margin.
PBYI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.1M | +1.1% |
| Q2 2026 | $56.5M | +7.8% |
| Q1 2026 | $44.8M | -2.6% |
| Q4 2025 | $75.5M | +28% |
| Q3 2025 | $54.5M | -32% |
| Q2 2025 | $52.4M | +11% |
| Q1 2025 | $46M | +5.1% |
| Q4 2024 | $59.1M | -18% |
PBYI's revenue is growing: $55M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | -8 points |
| Q2 2026 | 13% | +0.8 points |
| Q1 2026 | -8.5% | -17 points |
| Q4 2025 | 23% | +0.1 points |
| Q3 2025 | 18% | -9.8 points |
| Q2 2025 | 13% | +17 points |
| Q1 2025 | 8.7% | +14 points |
| Q4 2024 | 23% | +2.1 points |
PBYI's operating margin was 9.6% last quarter, down 8 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PBYI on cash flow, with more consistent year-over-year improvement.
PBYI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.6M | +51% |
| Q2 2026 | $1.6M | -88% |
| Q1 2026 | $15.4M | +334% |
| Q4 2025 | $14.5M | -7.3% |
| Q3 2025 | $9.7M | -12% |
| Q1 2025 | $3.6M | -68% |
| Q4 2024 | $15.6M | +50% |
| Q3 2024 | $11M | +4.1% |
PBYI generated $46M in free cash flow over the past year, up 7.5% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PBYI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PBYI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +520K shares |
| 1 year | +4.3% | +2.2M shares |
| 3 years | +11% | +5.3M shares |
| 5 years | +30% | +12.3M shares |
| Available history | +36% | +14.1M shares |
PBYI has 53M diluted shares, up 4.3% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PBYI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.1x | Net Cash |
PBYI has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PBYI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.6 | Neutral |
| Stochastic | 35.7 | Neutral |
PBYI's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PBYI PE vs Healthcare Sector
| Metric | PBYI | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 32% below |
| PE % | 70 | 29 | 41 pts above |
PBYI has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PBYI on trend strength, trading above more of its moving averages.
PBYI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.65 | 16% below |
| 20 week MA | $9.11 | 11% below |
| 50 week MA | $7.65 | 5.6% above |
| 100 week MA | $5.72 | 41% above |
| 200 week MA | $4.69 | 72% above |
PBYI has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 72% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PBYI on returns for 2026, with the stronger performance.
PBYI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.66 | $11.4 | +32% |
| 2021 | $11.4 | $3.46 | -70% |
| 2022 | $3.46 | $4.12 | +19% |
| 2023 | $4.12 | $4.33 | +5.1% |
| 2024 | $4.33 | $3.08 | -29% |
| 2025 | $3.08 | $6.16 | +100% |
| 2026 YTD | $6.16 | $8.08 | +31% |
PBYI's yearly returns have swung widely, from +100% in 2025 to −70% in 2021. It's up 31% so far in 2026.